PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer

被引：10

作者：

Akiki, Mira ^{[1
]}

Haddad, Fady Gh ^{[2
]}

Kourie, Hampig Raphael ^{[2
]}

Khaddage, Abir ^{[1
]}

Smayra, Viviane Track ^{[1
]}

机构：

[1] St Joseph Univ, Fac Med, Pathol Dept, Beirut, Lebanon

[2] St Joseph Univ, Fac Med, Hematol & Oncol Dept, Beirut, Lebanon

来源：

BIOMARKERS IN MEDICINE | 2019年 / 13卷 / 18期

关键词：

breast cancer; clinical trials; immunotherapy; oncology; PD-L1; TNBC; triple negative; EXPRESSION;

D O I：

10.2217/bmm-2019-0344

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：1539 / 1541

页数：3

共 12 条

[1] The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis [J].

Aguiar, Pedro N., Jr. ;

Santoro, Ilka Lopes ;

Tadokoro, Hakaru ;

Lopes, Gilberto de Lima ;

Filardi, Bruno Andraus ;

Oliveira, Pedro ;

Mountzios, Giannis ;

de Mello, Ramon Andrade .

IMMUNOTHERAPY, 2016, 8 (04) :479-488

[2] Metastatic and triple-negative breast cancer: challenges and treatment options [J].

Al-Mahmood, Sumayah ;

Sapiezynski, Justin ;

Garbuzenko, Olga B. ;

Minko, Tamara .

DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2018, 8 (05) :1483-1507

[3]

Anders Carey K, 2016, Am Soc Clin Oncol Educ Book, V35, P34, DOI 10.14694/EDBK_159135

[4]

[Anonymous], 2018, THE ASCO POST

[5] PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas [J].

Cimino-Mathews, Ashley ;

Thompson, Elizabeth ;

Taube, Janis M. ;

Ye, Xiaobu ;

Lu, Yao ;

Meeker, Alan ;

Xu, Haiying ;

Sharma, Rajni ;

Lecksell, Kristen ;

Cornish, Toby C. ;

Cuka, Nathan ;

Argani, Pedram ;

Emens, Leisha A. .

HUMAN PATHOLOGY, 2016, 47 (01) :52-63

[6] PD-1 and its ligands in tolerance and immunity [J].

Keir, Mary E. ;

Butte, Manish J. ;

Freeman, Gordon J. ;

Sharpel, Arlene H. .

ANNUAL REVIEW OF IMMUNOLOGY, 2008, 26 :677-704

[7] Recent advances in triple negative breast cancer: the immunotherapy era [J].

Marra, Antonio ;

Viale, Giulia ;

Curigliano, Giuseppe .

BMC MEDICINE, 2019, 17

[8] CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms [J].

Parry, RV ;

Chemnitz, JM ;

Frauwirth, KA ;

Lanfranco, AR ;

Braunstein, I ;

Kobayashi, SV ;

Linsley, PS ;

Thompson, CB ;

Riley, JL .

MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (21) :9543-9553

[9] Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Vandormael, Kristel ;

Riccio, Antonio ;

Yang, Jing ;

Pietanza, M. Catherine ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) :537-+

[10]

Roche, 2019, VENTANA PD L1 SP142

← 1 2 →